CD40LG and metabolic dysfunction-associated steatohepatitis: To evaluate the diagnostic value of IgM-free AIM, sera from the non-HCC (chronic hepatitis and cirrhosis) patient group and the HCC patient group including all cancer stages related to NASH, HCV, and HBV were measured with ECLIA using the anti-AIM antibody No. 12 and No. 11.